Literature DB >> 21947783

The virulence gene and clinical phenotypes of osteopetrosis in the Chinese population: six novel mutations of the CLCN7 gene in twelve osteopetrosis families.

Chun Wang1, Hao Zhang, Jin-Wei He, Jie-Mei Gu, Wei-Wei Hu, Yun-Qiu Hu, Miao Li, Yu-Juan Liu, Wen-Zhen Fu, Hua Yue, Yao-Hua Ke, Zhen-Lin Zhang.   

Abstract

Osteopetrosis is a heritable bone disorder resulting from a deficiency of or a functional defect in osteoclasts. We aimed to characterize the molecular defects and clinical manifestations in Chinese patients with osteopetrosis by studying 12 unrelated osteopetrosis families. The entire coding region and adjacent splice sites of the CLCN7, TCIRG1, LRP5 and SOST genes were amplified and directly sequenced. X-rays of hip and lumbar spine, bone mineral density and bone turnover markers were examined simultaneously. Family history and fracture history were collected using a questionnaire. Among 12 unrelated families, 10 families were diagnosed with autosomal dominant osteopetrosis type II (ADOII) with 10 probands and 3 affected subjects. Two individuals in the other two families were diagnosed with uncategorized osteopetrosis because no mutations were detected in any of the four studied genes. Eight mutations, including two reported mutations (R767W and E798FS) and six novel mutations (E313K, A316G, R743W, G741R, W127G and S290F), were detected in the CLCN7 gene from 12 living ADOII patients. Among them, R767W and R743W mutations were two common mutations that were each found in 20% of 10 ADOII probands. In CLCN7-related ADOII patients, long bone fractures and elevated serum CK level were two major clinical phenotypes, especially in patients younger than 18 years. Further functional studies of the above eight mutations in the CLCN7 gene are needed in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947783     DOI: 10.1007/s00774-011-0319-z

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  29 in total

1.  Chloride channel CICN7 mutations in a Korean patient with infantile malignant osteopetrosis initially presenting with neonatal thrombocytopenia.

Authors:  Youn-Jeong Shin
Journal:  J Perinatol       Date:  2004-05       Impact factor: 2.521

Review 2.  Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form.

Authors:  C C Johnston; N Lavy; T Lord; F Vellios; A D Merritt; W P Deiss
Journal:  Medicine (Baltimore)       Date:  1968-03       Impact factor: 1.889

3.  Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders.

Authors:  M P Whyte; A Chines; D P Silva; Y Landt; J H Ladenson
Journal:  J Bone Miner Res       Date:  1996-10       Impact factor: 6.741

4.  DNA-based diagnosis of malignant osteopetrosis by whole-genome scan using a single-nucleotide polymorphism microarray: standardization of molecular investigations of genetic diseases due to consanguinity.

Authors:  Ching-Wan Lam; Sui-Fan Tong; Keong Wong; Y F Luo; Hoi-Yin Tang; Shau-Yin Ha; Michael Ho-Ming Chan
Journal:  J Hum Genet       Date:  2006-10-11       Impact factor: 3.172

5.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors:  T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal:  J Bone Miner Res       Date:  2000-04       Impact factor: 6.741

6.  Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation.

Authors:  Steven G Waguespack; Siu L Hui; Linda A Dimeglio; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2006-12-12       Impact factor: 5.958

7.  Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.

Authors:  Liesbeth Van Wesenbeeck; Erna Cleiren; Jeppe Gram; Rodney K Beals; Olivier Bénichou; Domenico Scopelliti; Lyndon Key; Tara Renton; Cindy Bartels; Yaoqin Gong; Matthew L Warman; Marie-Christine De Vernejoul; Jens Bollerslev; Wim Van Hul
Journal:  Am J Hum Genet       Date:  2003-02-10       Impact factor: 11.025

8.  Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II).

Authors:  Zhen-Lin Zhang; Jin-Wei He; Hao Zhang; Wei-Wei Hu; Wen-Zhen Fu; Jie-Mei Gu; Jin-Bo Yu; Gao Gao; Yun-Qiu Hu; Miao Li; Yu-Juan Liu
Journal:  J Bone Miner Metab       Date:  2009-03-14       Impact factor: 2.626

9.  Characteristics of ClC7 Cl- channels and their inhibition in mutant (G215R) associated with autosomal dominant osteopetrosis type II in native osteoclasts and hClcn7 gene-expressing cells.

Authors:  Hiroshi Kajiya; Fujio Okamoto; Kimiko Ohgi; Akihiro Nakao; Hidefumi Fukushima; Koji Okabe
Journal:  Pflugers Arch       Date:  2009-06-19       Impact factor: 3.657

10.  Type II benign osteopetrosis (Albers-Schönberg disease) caused by a novel mutation in CLCN7 presenting with unusual clinical manifestations.

Authors:  C Letizia; A Taranta; S Migliaccio; C Caliumi; D Diacinti; E Delfini; E D'Erasmo; M Iacobini; M Roggini; O M E Albagha; S H Ralston; A Teti
Journal:  Calcif Tissue Int       Date:  2003-11-26       Impact factor: 4.333

View more
  10 in total

1.  Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients.

Authors:  Q Pang; Y Chi; Z Zhao; X Xing; M Li; O Wang; Y Jiang; R Liao; Y Sun; J Dong; W Xia
Journal:  Osteoporos Int       Date:  2015-09-22       Impact factor: 4.507

2.  Two novel mutations of CLCN7 gene in Chinese families with autosomal dominant osteopetrosis (type II).

Authors:  Hui Zheng; Chong Shao; Yan Zheng; Jin-Wei He; Wen-Zhen Fu; Chun Wang; Zhen-Lin Zhang
Journal:  J Bone Miner Metab       Date:  2015-06-09       Impact factor: 2.626

3.  Autosomal dominant osteopetrosis type II resulting from a de novo mutation in the CLCN7 gene: A case report.

Authors:  Xiu-Li Song; Li-Yuan Peng; Dao-Wen Wang; Hong Wang
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

4.  Differentially expressed genes in autosomal dominant osteopetrosis type II osteoclasts reveal known and novel pathways for osteoclast biology.

Authors:  Amélie E Coudert; Andrea Del Fattore; Céline Baulard; Robert Olaso; Corinne Schiltz; Corinne Collet; Anna Teti; Marie-Christine de Vernejoul
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

5.  Novel CLCN7 mutation identified in a Han Chinese family with autosomal dominant osteopetrosis-2.

Authors:  Hao Deng; Dan He; Pengfei Rong; Hongbo Xu; Lamei Yuan; Liu Li; Qian Lu; Yi Guo
Journal:  Mol Pain       Date:  2016-06-20       Impact factor: 3.395

6.  Enhanced but hypofunctional osteoclastogenesis in an autosomal dominant osteopetrosis type II case carrying a c.1856C>T mutation in CLCN7.

Authors:  Xiang Chen; Kun Zhang; Janet Hock; Chunyu Wang; Xijie Yu
Journal:  Bone Res       Date:  2016-11-29       Impact factor: 13.567

7.  Lessons Learned from Long-Term Management of Hip Fracture in Patients with Osteopetrosis: A Report of Nine Hips in Five Patients.

Authors:  Jae-Young Lim; Boo Seop Kim; Byung-Ho Yoon; Jae Suk Chang; Chan-Ho Park; Kyung-Hoi Koo
Journal:  J Bone Metab       Date:  2019-08-31

8.  Clinical and molecular characterization of five Chinese patients with autosomal recessive osteopetrosis.

Authors:  Huanhuan Liang; Niu Li; Ru-En Yao; Tingting Yu; Lixia Ding; Jing Chen; Jian Wang
Journal:  Mol Genet Genomic Med       Date:  2021-09-21       Impact factor: 2.183

Review 9.  The Role of the Lysosomal Cl-/H+ Antiporter ClC-7 in Osteopetrosis and Neurodegeneration.

Authors:  Giovanni Zifarelli
Journal:  Cells       Date:  2022-01-21       Impact factor: 6.600

10.  Natural History of Type II Autosomal Dominant Osteopetrosis: A Single Center Retrospective Study.

Authors:  Ziyuan Wang; Xiang Li; Ya Wang; Wenzhen Fu; Yujuan Liu; Zhenlin Zhang; Chun Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-17       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.